Prosecution Insights
Last updated: April 19, 2026
Application No. 18/690,584

NONINVASIVE SYSTEM AND METHOD FOR MEASURING HYPOGLYCEMIA AND HYPERGLYCEMIA

Non-Final OA §103
Filed
Mar 08, 2024
Examiner
TOMASZEWSKI, MICHAEL
Art Unit
3681
Tech Center
3600 — Transportation & Electronic Commerce
Assignee
BECTON, DICKINSON AND COMPANY
OA Round
1 (Non-Final)
47%
Grant Probability
Moderate
1-2
OA Rounds
2y 11m
To Grant
70%
With Interview

Examiner Intelligence

Grants 47% of resolved cases
47%
Career Allow Rate
271 granted / 572 resolved
-4.6% vs TC avg
Strong +23% interview lift
Without
With
+23.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
27 currently pending
Career history
599
Total Applications
across all art units

Statute-Specific Performance

§101
53.3%
+13.3% vs TC avg
§103
35.9%
-4.1% vs TC avg
§102
1.8%
-38.2% vs TC avg
§112
4.9%
-35.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 572 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Notice to Applicant 2. This communication is in response to the communication filed 3/8/2024. Claims 6-15 and second claim 5 are cancelled. Claims 16-26 are new. Claims 1-5 and 16-26 are currently pending. Claim Rejections - 35 USC § 103 3. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. 3.1. Claims 1-5, 17-21, and 23-26 are rejected under 35 U.S.C. 103 as being unpatentable over Perez et al. (US 2017/0021171), in view of Connor (US 2017/0164878). CLAIM 1 Perez teaches a wearable unit (Perez: abstract) comprising: a housing configured to be worn on a body of a patient (Perez: abstract; ¶¶ [0372] “electro-dermal patch device is wearable”, [0403] “housing”, [0577]-[0579]; FIGS. 21A-21B); and an electronics module (Perez: abstract; ¶¶ [0372] “electro-dermal patch device”, [0577]-[0579]; FIGS. 21A-21B) comprising: a power source (Perez: abstract; ¶¶ [0401] “a power management module 120, such as a lithium-ion battery, a betavoltaic battery, a solar cell, nickel-cadmium battery, or a fuel cell. In some embodiments, the power management module 120 comprises a battery having a voltage”, [0577]-[0579]; FIGS. 1A-1F, 21A-21B); plurality of sensors comprising a temperature sensor configured to sense a temperature of the patient, a pulse oximeter configured to sense an oxygen saturation of the patient, an accelerometer configured to sense a breathing pattern of the patient, a skin conductance sensor configured to sense a skin conductance of the patient, and an electrocardiogram (ECG) monitor configured to sense an ECG pattern of the patient (Perez: abstract; ¶¶ [0238], [0402], [0404]-[0405]; Table 1; FIGS. 1A-5F); and a microcontroller configured to receive an output from one or more of the plurality of sensors and to determine, whether the output indicates one of hyperglycemia (Perez: abstract; ¶¶ [0392] “microcontroller”, [0401], [0512] “detect conditions such as a hyperglycemic”; FIGS. 1A-5F, 21A-21B). Perez does not appear to explicitly teach the following: and hypoglycemia. Connor, however, teaches the following: and hypoglycemia (Connor: abstract; ¶¶ [0400] “detect, predict, reduce, and/or avoid hypoglycemia, hyperglycemia”; FIGS. 1-72). It would have been obvious to one of ordinary skill in the art, before the effective filing date of the claimed invention, to include the wearable technology for non-invasive glucose monitoring, as taught by Connor, with the electro-dermal patch with sensors, as taught by Perez, with the motivation of providing a more accurate non-invasive measurement of body glucose levels (Connor: abstract; ¶¶ [0014]-[0015]). CLAIM 2 Perez teaches the wearable unit according to claim 1, further comprising: a wristband configured to attach the housing to a wrist of the patient (Perez: abstract; ¶¶ [0577] “wristband”; FIGS. 21A-21B). CLAIM 3 Perez teaches the wearable unit according to claim 2, the microcontroller further comprising a Bluetooth module, wherein the microcontroller is further configured to transmit information to an external device, the information comprising at least one of the output from the one or more of the plurality of sensors and a determination of whether the output indicates one of hyperglycemia and hypoglycemia (Perez: abstract; ¶¶ [0400] “system 100 comprises an electro-dermal patch (EDP) device 110 in data communication with a companion device 105…Bluetooth”; FIGS. 1A-1F, 21A-21B). CLAIM 4 Perez does not appear to explicitly teach the wearable unit according to claim 1, further comprising: an earpiece configured to hold the housing within an ear of the patient. Connor, however, teaches further comprising: an earpiece configured to hold the housing within an ear of the patient (Connor: abstract; ¶¶ [0354]-[0358] “an ear-worn diagnostic component can be an ear-inserted component which is inserted (partially or fully) into an ear canal”; FIGS. 1-72). The motivation to include the teachings of Connor with the teachings of Perez is the same as that of claim 1 above and is incorporated herein. CLAIM 5 Perez teaches the wearable unit according to claim 4, the microcontroller further comprising a Bluetooth module, wherein the microcontroller is further configured to transmit information to an external device, the information comprising at least one of the output from the one or more of the plurality of sensors and a determination of whether the output indicates one of hyperglycemia and hypoglycemia (Perez: abstract; ¶¶ [0400] “system 100 comprises an electro-dermal patch (EDP) device 110 in data communication with a companion device 105…Bluetooth”; FIGS. 1A-1F, 21A-21B). CLAIM 17 Perez teaches a sensing system (Perez: abstract) comprising: an external device (Perez: abstract; ¶¶ [0372] “electro-dermal patch device”, [0403], [0577]-[0579]; FIGS. 21A-21B); and a wearable unit (Perez: abstract; ¶¶ [0372] “electro-dermal patch device is wearable”, [0403], [0577]-[0579]; FIGS. 21A-21B) comprising: a housing configured to be worn on a body of a patient (Perez: abstract; ¶¶ [0372] “electro-dermal patch device is wearable”, [0403] “housing”, [0577]-[0579]; FIGS. 21A-21B); and an electronics module (Perez: abstract; ¶¶ [0401]-[0404] “electro-dermal patch device”; FIGS. 1-45) comprising: a power source (Perez: abstract; ¶¶ [0401] “a power management module 120, such as a lithium-ion battery, a betavoltaic battery, a solar cell, nickel-cadmium battery, or a fuel cell. In some embodiments, the power management module 120 comprises a battery having a voltage”, [0577]-[0579]; FIGS. 1A-1F, 21A-21B); a plurality of sensors comprising a temperature sensor configured to sense a temperature of the patient, a pulse oximeter configured to sense an oxygen saturation of the patient, an accelerometer configured to sense a breathing pattern of the patient, a skin conductance sensor configured to sense a skin conductance of the patient, and an electrocardiogram (ECG) monitor configured to sense an ECG pattern of the patient (Perez: abstract; ¶¶ [0238], [0402], [0404]-[0405]; Table 1; FIGS. 1A-5F); a transmission unit (Perez: abstract; ¶¶ [0413]-[0416], [0485]-[0487]; FIGS. 1A-6F, 21A-21B ); and a microcontroller (Perez: abstract; ¶¶ [0392] “microcontroller”, [0401]; FIGS. 1A-5F, 21A-21B) configured to: receive an output from one or more of the plurality of sensors (Perez: abstract; ¶¶ [0413]-[0416], [0485]-[0487]; FIGS. 1A-6F, 21A-21B), and control the transmission unit to output, to the external device, information comprising the output from the one or more of the plurality of sensors (Perez: abstract; ¶¶ [0413]-[0416], [0485]-[0487]; FIGS. 1A-6F, 21A-21B); wherein the external device is configured to receive the information from the wearable device and to determine whether the output indicates one of hyperglycemia (Perez: abstract; ¶¶ [0392], [0401], [0512] “detect conditions such as a hyperglycemic”; FIGS. 1A-5F, 21A-21B). Perez does not appear to explicitly teach the following: and hypoglycemia. Connor, however, teaches the following: and hypoglycemia (Connor: abstract; ¶¶ [0400] “detect, predict, reduce, and/or avoid hypoglycemia, hyperglycemia”; FIGS. 1-72). The motivation to include the teachings of Connor with the teachings of Perez is the same as that of claim 1 above and is incorporated herein. CLAIM 18 Perez teaches the sensing system according to claim 17, the wearable unit further comprising a wristband configured to attach the housing to a wrist of the patient (Perez: abstract; ¶¶ [0577] “wristband”; FIGS. 21A-21B). CLAIM 19 Perez teaches the sensing system according to claim 17, wherein the transmission unit comprises a Bluetooth module (Perez: abstract; ¶¶ [0400] “system 100 comprises an electro-dermal patch (EDP) device 110 in data communication with a companion device 105…Bluetooth”; FIGS. 1A-1F, 21A-21B). CLAIM 20 Perez does not appear to explicitly teach the sensing system according to claim 17, the wearable unit further comprising an earpiece configured to hold the housing within an ear of the patient. Connor, however, teaches the wearable unit further comprising an earpiece configured to hold the housing within an ear of the patient (Connor: abstract; ¶¶ [0354]-[0358] “an ear-worn diagnostic component can be an ear-inserted component which is inserted (partially or fully) into an ear canal”; FIGS. 1-72). The motivation to include the teachings of Connor with the teachings of Perez is the same as that of claim 1 above and is incorporated herein. CLAIM 21 Perez teaches the sensing system according to claim 20, wherein the transmission unit comprises a Bluetooth module (Perez: abstract; ¶¶ [0400] “system 100 comprises an electro-dermal patch (EDP) device 110 in data communication with a companion device 105…Bluetooth”; FIGS. 1A-1F, 21A-21B). CLAIMS 23-26 Claims 23-26 repeat substantially the same limitations as those in claims 1-4. As such, claims 23-26 are rejected for substantially the same reasons given for claims 1-4 and are incorporated herein. 3.2. Claims 16 and 22 are rejected under 35 U.S.C. 103 as being unpatentable over Perez et al. (US 2017/0021171), in view of Connor (US 2017/0164878), and further in view of Zribi et al. (US 2007/0004975). CLAIM 16 Perez and Connor do not appear to explicitly teach the wearable unit according to claim 1, the electronics module further comprising: an output unit, wherein the microcontroller is further configured to output at least one of a visible alert and an audible alert to the patient based on whether the output indicates one of hyperglycemia and hypoglycemia. Zribi, however, teaches the electronics module further comprising: an output unit, wherein the microcontroller is further configured to output at least one of a visible alert and an audible alert to the patient based on whether the output indicates one of hyperglycemia and hypoglycemia (Zribi: abstract; ¶¶ [0028] “analysis unit may generate alerts based on the glucose levels via a routine embedded with a processor in the analysis unit. For example, in conditions such as hypoglycemia or hyperglycemia, the portable analysis unit may generate an audible (such as an alarm or audio notification) and/or a visual alert (such as a text alert, light indication, color indication, and so forth)”; FIGS. 1-4). It would have been obvious to one of ordinary skill in the art, before the effective filing date of the claimed invention, to include the non-invasive glucose monitoring system, as taught by Zribi, with the wearable technology for non-invasive glucose monitoring, as taught by Connor, with the electro-dermal patch with sensors, as taught by Perez, with the motivation of providing improved monitoring and management of glucose levels (Zribi: abstract; ¶¶ [0001]-[0008], [0028]). CLAIM 22 Perez and Connor do not appear to explicitly teach the sensing system according to claim 17, wherein the external device is further configured to determine to output at least one of a visible alert and an audible alert to the patient based on whether the output indicates one of hyperglycemia and hypoglycemia. Zribi, however, teaches wherein the external device is further configured to determine to output at least one of a visible alert and an audible alert to the patient based on whether the output indicates one of hyperglycemia and hypoglycemia (Zribi: abstract; ¶¶ [0028] “analysis unit may generate alerts based on the glucose levels via a routine embedded with a processor in the analysis unit. For example, in conditions such as hypoglycemia or hyperglycemia, the portable analysis unit may generate an audible (such as an alarm or audio notification) and/or a visual alert (such as a text alert, light indication, color indication, and so forth)”; FIGS. 1-4). The motivation to include the teachings of Zribi with the teachings of Perez and Connor is the same as that of claim 16 above and is incorporated herein. Conclusion 4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Tomaszewski whose telephone number is (313)446-4863. The examiner can normally be reached M-F 5:30 am - 2:30 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Peter H Choi can be reached at (469) 295-9171. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL TOMASZEWSKI/Primary Examiner, Art Unit 3681
Read full office action

Prosecution Timeline

Mar 08, 2024
Application Filed
Dec 15, 2025
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12592900
METHOD AND APPARATUS FOR MESSAGING SERVICE
2y 5m to grant Granted Mar 31, 2026
Patent 12567490
DEEP-LEARNING-BASED MEDICAL IMAGE INTERPRETATION SYSTEM FOR ANIMALS
2y 5m to grant Granted Mar 03, 2026
Patent 12561751
DIGITAL COPYRIGHT CREATION MODULE FOR DIGITAL CONTENT CREATED USING GENERATIVE AI, AND DIGITAL CONTENT DISTRIBUTION APPARATUS AND METHOD USING THE SAME
2y 5m to grant Granted Feb 24, 2026
Patent 12548682
SYSTEM AND METHOD FOR OUTCOME TRACKING AND ANALYSIS
2y 5m to grant Granted Feb 10, 2026
Patent 12525329
PRECISION-BASED IMMUNO-MOLECULAR AUGMENTATION (PBIMA) COMPUTERIZED SYSTEM, METHOD, AND THERAPEUTIC VACCINE
2y 5m to grant Granted Jan 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
47%
Grant Probability
70%
With Interview (+23.1%)
2y 11m
Median Time to Grant
Low
PTA Risk
Based on 572 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month